Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Tumor Tissue (FFPE)
Sample Type
8 Working Days
Turnaround Time ¹
ACTLung™ targets 13 common driver genes and assists newly diagnosed lung cancer patients to rapidly determine a first-line targeted therapy opportunity.
Precision Medicine to Plan Better Treatment
Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.
Why ACT Genomics?
Humane Process
Avoid multiple biopsies and time cost of single-gene test, few specimens required for various fusion gene detection at once.
Ideal Treatment
Find proper targeted options.
Smart Budgeting
Evaluate options before treatment according to genomic information, to ensure success rate and avoid waste of medical budget.
Learn More
How to Make Sure the Bull's Eye is Targeted in Your Treatment?
When it comes to a big decision in life, you can't be careful enough, including your targeted therapy. There are often more than one target in tumor, and if you shoot them with a strategy rather than one guesswork after another can often make tumor into controlled, while most people don't realize the difference and lose the chance in the beginning. Cancer genomic profiling enables major targets to be revealed all at once such as EGFR, ALK, ROS1…etc, and by identifying the driver gene, you can target at the bull's eye and increase chance of having a successful treatment.
Common Problems in Lung Cancer Treatment
- Chemotherapy and surgery are the only options according to NCCN guidelines or single-gene test result
- Complicated and metastases, hard to know the appropriate drugs
- Ineffective treatment, and cancer relapse after targeted therapy
- Pursue for immunotherapy, targeted therapy and wondering the effect
Diagnostic Solutions for Newly Diagnosed Lung Cancer Patients
Through Next Generation Sequencing (NGS), ACTLung™ targeted genomic profiling decodes 13 lung cancer-related genes to map drug options via clinical guidelines, enable more treatment strategies with higher success rate.
Who Is Suitable for ACTLung™?
- Non-small cell lung cancer (NSCLC)
- Newly diagnosed and metastatic cancer
Documentation
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.
